Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23778643 | 0.99 | MTNR1A (0.47) | MTNR1ATRPV1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL23778733 | 0.91 | THRB (0.45) | MTNR1AALDH1A1MAPTHPGDTHRB | |
| SCHEMBL23778699 | 0.83 | CA1 (0.43) | ALDH1A1MEN1KMT2AHPGDTHRB | |
| SCHEMBL23778677 | 0.82 | THRB (0.41) | ALDH1A1MAPTHSD17B10THRBPOLB | |
| SCHEMBL23778650 | 0.81 | MTNR1A (0.48) | MTNR1AMAPTHSD17B10MEN1KMT2A | |
| SCHEMBL23778661 | 0.81 | SMN1; SMN2 (0.41) | ALDH1A1MAPTHSD17B10MEN1KMT2A | |
| SCHEMBL23778670 | 0.81 | TP53 (0.46) | ALDH1A1MAPTMEN1KMT2ATHRB | |
| SCHEMBL23778656 | 0.81 | KDM4E (0.44) | ALDH1A1MAPTHSD17B10HPGDTHRB | |
| SCHEMBL23778721 | 0.80 | ADORA3 (0.45) | MTNR1AALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL23778698 | 0.80 | TP53 (0.41) | MAPTMEN1KMT2AHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2025-08-05 | — | — | US | claimed |
| EP-3873890-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | Ahammune Biosciences Private Limited (IN) | 2021-09-08 | — | — | EP | claimed |
| US-20260001850-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) | 2026-01-01 | — | — | US | disclosed |
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2025-08-05 | — | — | US | disclosed |
| US-20210380538-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) | 2021-12-09 | — | — | US | disclosed |
| EP-3873890-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | Ahammune Biosciences Private Limited (IN) | 2021-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380538-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | IDO1, IDO2, NFATC1 | MTNR1A 1790/4885TRPV1 642/4885ALDH1A1 670/4885 |
| US-20260001850-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | MALT1, ADRM1, CYP11B1 | MTNR1A 306/4885TRPV1 781/4885ALDH1A1 2523/4885 |
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | IDO1, IDO2, NFATC1 | MTNR1A 2087/4885TRPV1 712/4885ALDH1A1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.